1887
  1. Home
  2. Eurosurveillance
  3. Volume 24, Issue 38, 19/Sep/2019
  4. Article
Research Open Access
Like 1
Download

Abstract

Introduction

In 2015, there was an increase in the number of asylum seekers arriving in Europe. Like in other countries, deciding screening priorities for tuberculosis (TB) and meticillin-resistant (MRSA) was a challenge. At least five of 428 municipalities chose to screen asylum seekers for MRSA before TB; the Norwegian Institute for Public Health advised against this.

Aim

To evaluate the MRSA/TB screening results from 2014 to 2016 and create a generalised framework for screening prioritisation in Norway through simulation modelling.

Methods

This is a register-based cohort study of asylum seekers using data from the Norwegian Surveillance System for Communicable Diseases from 2014 to 2016. We used survey data from municipalities that screened all asylum seekers for MRSA and denominator data from the Directorate of Immigration. A comparative risk assessment model was built to investigate the outcomes of prioritising between TB and MRSA in screening regimes.

Results

Of 46,090 asylum seekers, 137 (0.30%) were diagnosed with active TB (notification rate: 300/100,000 person-years). In the municipalities that screened all asylum seekers for MRSA, 13 of 1,768 (0.74%) were found to be infected with MRSA. The model estimated that screening for MRSA would prevent eight MRSA infections while prioritising TB screening would prevent 24 cases of active TB and one death.

Conclusion

Our findings support the decision to advise against screening for MRSA before TB among newly arrived asylum seekers. The model was an effective tool for comparing screening priorities and can be applied to other scenarios in other countries.

© Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
Loading

Article metrics loading...

/content/10.2807/1560-7917.ES.2019.24.38.1800676
2019-09-19
2024-12-24
/content/10.2807/1560-7917.ES.2019.24.38.1800676
Loading
Loading full text...

Full text loading...

/deliver/fulltext/eurosurveillance/24/38/eurosurv-24-38-4.html?itemId=/content/10.2807/1560-7917.ES.2019.24.38.1800676&mimeType=html&fmt=ahah

References

  1. World Health Organization (WHO). The top 10 causes of death: Fact sheet. Geneva: WHO; 2017. Available from: http://www.who.int/mediacentre/factsheets/fs310/en/
  2. World Health Organization (WHO). Tuberculosis: Fact sheet. Geneva: WHO; 2017. Available from: http://www.who.int/mediacentre/factsheets/fs104/en/
  3. Houben RM, Dodd PJ. The Global Burden of Latent Tuberculosis Infection: A Re-estimation Using Mathematical Modelling. PLoS Med. 2016;13(10):e1002152.  https://doi.org/10.1371/journal.pmed.1002152  PMID: 27780211 
  4. World Health Organization (WHO). Antimicrobial resistance: global report on surveillance. Geneva: WHO; 2014.Available from: https://apps.who.int/iris/bitstream/handle/10665/112642/9789241564748_eng.pdf;jsessionid=5AC7F83956032F0E0D48B65EA27A8EF2?sequence=1
  5. Cassini A, Högberg LD, Plachouras D, Quattrocchi A, Hoxha A, Simonsen GS, et al. Burden of AMR Collaborative Group. Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the EU and the European Economic Area in 2015: a population-level modelling analysis. Lancet Infect Dis. 2019;19(1):56-66.  https://doi.org/10.1016/S1473-3099(18)30605-4  PMID: 30409683 
  6. Norwegian Institute of Public Health (NIPH). Tuberkulose i Norge 2016 – med behandlingsresultater for 2015. Årsrapport. Delrapport 5 av smittsomme sykdommer i Norge. [Tuberculosis in Norway 2016 – with treatment results for 2015. Yearly report. Part 5 of infectious diseases in Norway]. Oslo: NIPH; 2017. Norwegian. Available from: https://www.fhi.no/globalassets/dokumenterfiler/rapporter/2015/tuberkulose-i-norge-i-2016---med-behandlingsresultater-for-2015.pdf
  7. NORM/NORM-VET. 2016. Usage of Antimicrobial Agents and Occurrence of Antimicrobial Resistance in Norway. Tromsø/Oslo: Norwegian Veterinary Institute/Norwegian Institute of Public Health; 2017. Available from: https://unn.no/Documents/Kompetansetjenester,%20-sentre%20og%20fagr%C3%A5d/NORM%20-%20Norsk%20overv%C3%A5kingssystem%20for%20antibiotikaresistens%20hos%20mikrober/Rapporter/NORM%20NORM-VET%202016.pdf
  8. World Health Organization (WHO). IHR Procedures concerning public health emergencies of international concern (PHEIC). Geneva: WHO; 2016. Available from: http://www.who.int/ihr/procedures/pheic/en/
  9. Jorgensen SB, Handal N, Fjeldsaeter KL, Kleppe LK, Myrbakk T, Oma DH, et al. MRSA prevalence among healthcare personnel in contact tracings in hospitals. Tidsskriftete for den Norske laegeforening. 2018;138(6). Available from: https://tidsskriftet.no/en/2018/03/originalartikkel/mrsa-prevalence-among-healthcare-personnel-contact-tracings-hospitals.
  10. Eiset AH, Wejse C. Review of infectious diseases in refugees and asylum seekers-current status and going forward. Public Health Rev. 2017;38(1):22.  https://doi.org/10.1186/s40985-017-0065-4  PMID: 29450094 
  11. European Centre for Disease Prevention and Control (ECDC). Expert Opinion on the public health needs of irregular migrants, refugees or asylum seekers across the EU's southern and south-eastern borders. Stockholm: ECDC; 2015. Available from: http://ecdc.europa.eu/en/publications/Publications/Expert-opinion-irregular-migrants-public-health-needs-Sept-2015.pdf
  12. Norwegian Institute of Public Health (NIPH). Routine screening for tuberculosis (TB). Oslo: NIPH; 2017. Available from: https://www.fhi.no/en/id/infectious-diseases/TB/routine-screening-tb/
  13. Norwegian Institute of Public Health (NIPH). MRSA-veilederen [The MRSA guide]. Oslo: NIPH; 2009. Norwegian. Available from: https://www.fhi.no/globalassets/migrering/dokumenter/pdf/mrsa-veilederen.pdf
  14. Elstrøm P, Astrup E, Hegstad K, Samuelsen Ø, Enger H, Kacelnik O. The fight to keep resistance at bay, epidemiology of carbapenemase producing organisms (CPOs), vancomycin resistant enterococci (VRE) and methicillin resistant Staphylococcus aureus (MRSA) in Norway, 2006 - 2017. PLoS One. 2019;14(2):e0211741.  https://doi.org/10.1371/journal.pone.0211741  PMID: 30716133 
  15. Organisation for Economic Co-operation and Development (OECD). How resilient were OECD health care systems during the “refugee crisis”? Paris: OECD; 2018. Available from: http://www.oecd.org/migration/Migration-Policy-Debates-Nov2018-How-resilient-were-OECD-health-care-systems-during-the-refugee-crisis.pdf
  16. Langlois EV, Haines A, Tomson G, Ghaffar A. Refugees: towards better access to health-care services. Lancet. 2016;387(10016):319-21.  https://doi.org/10.1016/S0140-6736(16)00101-X  PMID: 26842434 
  17. Kunst H, Burman M, Arnesen TM, Fiebig L, Hergens MP, Kalkouni O, et al. Tuberculosis and latent tuberculous infection screening of migrants in Europe: comparative analysis of policies, surveillance systems and results. Int J Tuberc Lung Dis. 2017;21(8):840-51.  https://doi.org/10.5588/ijtld.17.0036  PMID: 28786791 
  18. Kärki T, Napoli C, Riccardo F, Fabiani M, Dente MG, Carballo M, et al. Screening for infectious diseases among newly arrived migrants in EU/EEA countries--varying practices but consensus on the utility of screening. Int J Environ Res Public Health. 2014;11(10):11004-14.  https://doi.org/10.3390/ijerph111011004  PMID: 25337945 
  19. Norwegian Directorate of Immigration (UDI). Tall og fakta 2015. [Numbers and facts 2015]. Oslo: UDI; 2016. Norwegian. Available from: https://www.udi.no/globalassets/global/aarsrapporter_i/tall-og-fakta-2015.pdf
  20. Norwegian Institute of Public Health (NIPH). Midlertidig forenkling av tuberkulosescreening av asylsøkere [Temporary simplification of tuberculosis screening of asylum seekers]. Oslo: NIPH; 2015. Norwegian. Available from: https://www.fhi.no/nyheter/2015/midlertidig-forenkling-av-tuberkulo/
  21. Asfeldt AM, Bratlien DL, Brekken A, Wikan NA, Ovesen T, Gravningen K. When Europe’s back door stood open. Tidsskr Nor Laegeforen. 2018;138(4). PMID: 29460593 
  22. Norwegian Institute of Public Health (NIPH). Undersøkelse for resistente bakterier – MRSA, VRE og ESBL-holdige bakterier i asylmottak. [Examination for resistant bacteria – MRSA, VRE and ESBL producing bacteria in asylum centers]. Oslo: NIPH; 2016. Norwegian. Available from: https://www.fhi.no/sv/asylsokeres-helse/undersokelse-for-resistente-bakteri/
  23. MSIS-forskriften. Forskrift om Meldingssystem for smittsomme sykdommer. [Regulation of the Norwegian Surveillance System for Communicable Diseases]. Oslo: Stortinget; 2003. Norwegian.Available from: https://lovdata.no/dokument/SF/forskrift/2003-06-20-740
  24. Guzman Herrador BR, Rønning K, Borgen K, Mannsåker T, Dahle UR. Description of the largest cluster of tuberculosis notified in Norway 1997-2011: is the Norwegian tuberculosis control programme serving its purpose for high risk groups? BMC Public Health. 2015;15(1):367.  https://doi.org/10.1186/s12889-015-1701-x  PMID: 25879411 
  25. Brennan A, Chick SE, Davies R. A taxonomy of model structures for economic evaluation of health technologies. Health Econ. 2006;15(12):1295-310.  https://doi.org/10.1002/hec.1148  PMID: 16941543 
  26. Tübbicke A, Hübner C, Kramer A, Hübner NO, Fleßa S. Transmission rates, screening methods and costs of MRSA--a systematic literature review related to the prevalence in Germany. Eur J Clin Microbiol Infect Dis. 2012;31(10):2497-511.  https://doi.org/10.1007/s10096-012-1632-8  PMID: 22573360 
  27. World Health Organization (WHO). Systematic screening for active tuberculosis: Principles and recommendations. Geneva: WHO; 2013.Available from: https://www.who.int/tb/publications/Final_TB_Screening_guidelines.pdf
  28. Straetemans M, Glaziou P, Bierrenbach AL, Sismanidis C, van der Werf MJ. Assessing tuberculosis case fatality ratio: a meta-analysis. PLoS One. 2011;6(6):e20755.  https://doi.org/10.1371/journal.pone.0020755  PMID: 21738585 
  29. Jonsen AR, Siegler M, Winslade WJ. Medical Indications. Clinical Ethics: A Practical Approach to Ethical Decisions in Clinical Medicine, 8e. New York: McGraw-Hill Education; 2015.
  30. Shenoy ES, Paras ML, Noubary F, Walensky RP, Hooper DC. Natural history of colonization with methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus (VRE): a systematic review. BMC Infect Dis. 2014;14(1):177.  https://doi.org/10.1186/1471-2334-14-177  PMID: 24678646 
  31. Council for International Organizations of Medical Sciences (CIOMS). International Ethical Guidelines for Health-Related Research Involving Humans. Geneva: CIOMS; 2016. Available from: https://cioms.ch/wp-content/uploads/2017/01/WEB-CIOMS-EthicalGuidelines.pdf
  32. Ravensbergen SJ, Berends M, Stienstra Y, Ott A. High prevalence of MRSA and ESBL among asylum seekers in the Netherlands. PLoS One. 2017;12(4):e0176481.  https://doi.org/10.1371/journal.pone.0176481  PMID: 28441421 
  33. Piso RJ, Käch R, Pop R, Zillig D, Schibli U, Bassetti S, et al. A Cross-Sectional Study of Colonization Rates with Methicillin-Resistant Staphylococcus aureus (MRSA) and Extended-Spectrum Beta-Lactamase (ESBL) and Carbapenemase-Producing Enterobacteriaceae in Four Swiss Refugee Centres. PLoS One. 2017;12(1):e0170251.  https://doi.org/10.1371/journal.pone.0170251  PMID: 28085966 
  34. Ackermann N, Marosevic D, Hörmansdorfer S, Eberle U, Rieder G, Treis B, et al. Screening for infectious diseases among newly arrived asylum seekers, Bavaria, Germany, 2015. Euro Surveill. 2018;23(10):17-00176.  https://doi.org/10.2807/1560-7917.ES.2018.23.10.17-00176  PMID: 29536830 
  35. World Health Organization (WHO). Global Tuberculosis Report 2017. Geneva: WHO; 2017. Available from: http://apps.who.int/iris/bitstream/handle/10665/259366/9789241565516-eng.pdf?sequence=1
  36. Wang X, Panchanathan S, Chowell G. A data-driven mathematical model of CA-MRSA transmission among age groups: evaluating the effect of control interventions. PLOS Comput Biol. 2013;9(11):e1003328.  https://doi.org/10.1371/journal.pcbi.1003328  PMID: 24277998 
  37. Sentralbyrå S. (SSB). Patient statistics, 2015. Oslo: SSB; 2017. Available from: https://www.ssb.no/en/helse/statistikker/pasient
  38. Hogea C, van Effelterre T, Acosta CJ. A basic dynamic transmission model of Staphylococcus aureus in the US population. Epidemiol Infect. 2014;142(3):468-78.  https://doi.org/10.1017/S0950268813001106  PMID: 23701989 
  39. Coello R, Glynn JR, Gaspar C, Picazo JJ, Fereres J. Risk factors for developing clinical infection with methicillin-resistant Staphylococcus aureus (MRSA) amongst hospital patients initially only colonized with MRSA. J Hosp Infect. 1997;37(1):39-46.  https://doi.org/10.1016/S0195-6701(97)90071-2  PMID: 9321727 
  40. Andreassen AES, Jacobsen CM, de Blasio B, White R, Kristiansen IS, Elstrøm P. The impact of methicillin-resistant S. aureus on length of stay, readmissions and costs: a register based case-control study of patients hospitalized in Norway. Antimicrob Resist Infect Control. 2017;6(1):74.  https://doi.org/10.1186/s13756-017-0232-x  PMID: 28694964 
  41. Tom S, Galbraith JC, Valiquette L, Jacobsson G, Collignon P, Schønheyder HC, et al. Case fatality ratio and mortality rate trends of community-onset Staphylococcus aureus bacteraemia. Clin Microbiol Infect. 2014;20(10):O630-2.  https://doi.org/10.1111/1469-0691.12564  PMID: 24461038 
  42. Lopes JS, Rodrigues P, Pinho ST, Andrade RF, Duarte R, Gomes MG. Interpreting measures of tuberculosis transmission: a case study on the Portuguese population. BMC Infect Dis. 2014;14(1):340.  https://doi.org/10.1186/1471-2334-14-340  PMID: 24941996 
  43. Ma Y, Horsburgh CR Jr, White LF, Jenkins HE. Quantifying TB transmission: a systematic review of reproduction number and serial interval estimates for tuberculosis. Epidemiol Infect. 2018;146(12):1478-94.  https://doi.org/10.1017/S0950268818001760  PMID: 29970199 
  44. Ozcaglar C, Shabbeer A, Vandenberg SL, Yener B, Bennett KP. Epidemiological models of Mycobacterium tuberculosis complex infections. Math Biosci. 2012;236(2):77-96.  https://doi.org/10.1016/j.mbs.2012.02.003  PMID: 22387570 
Targeting TB or MRSA in Norwegian municipalities during ‘the refugee crisis’ of 2015: a framework for priority setting in screening
<p class="citation"> <span>Citation style for this article:</span> <span class="meta-value authors"> <a href="/search?value1=Anders+Skyrud+Danielsen&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Danielsen Anders Skyrud</a>, <a href="/search?value1=Petter+Elstr%C3%B8m&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Elstrøm Petter</a>, <a href="/search?value1=Trude+Margrete+Arnesen&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Arnesen Trude Margrete</a>, <a href="/search?value1=Unni+Gopinathan&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Gopinathan Unni</a>, <a href="/search?value1=Oliver+Kacelnik&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Kacelnik Oliver</a></span>. Targeting TB or MRSA in Norwegian municipalities during ‘the refugee crisis’ of 2015: a framework for priority setting in screening. <a href="/content/ecdc">Euro Surveill.</a> 2019;24(38):pii=1800676. <a href="https://doi.org/10.2807/1560-7917.ES.2019.24.38.1800676" title="doi link" target="_blank">https://doi.org/10.2807/1560-7917.ES.2019.24.38.1800676</a> <span class="ES_Article_citation"> <span class="generated">Received</span>: 11 Dec 2018;&nbsp;&nbsp; <span class="generated">Accepted</span>: 14 May 2019 </span> </p>
/content/10.2807/1560-7917.ES.2019.24.38.1800676
/content/10.2807/1560-7917.ES.2019.24.38.1800676
Loading

Data & Media loading...

Supplementary data

Submit comment
Close
Comment moderation successfully completed
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error